Vaccines in late-stage development hold promise in tackling disease burden: GlobalData
According to GlobalData, there are 11 vaccines in late-stage development* for TB globally
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
infectious diseases
Moderna leads development of mRNA vaccines in infectious diseases: GlobalData
Moderna has Phase III pipeline candidates in four different indications (COVID-19, influenza, RSV, and cytomegalovirus) and is…
Bharat Biotech partners with Sydney ID to advance vaccine research in infectious diseases
The international agreement aims to build strong sectoral and cross-organisational collaborations to design novel methodologies to…
IIT Mandi researchers propose a protein-based vaccine against pork tapeworm
The team has combined protein studies and bioinformatics to identify safe and effective protein fragments for the vaccine
High levels of exposure to COVID virus may reduce protection from vaccination, prior infection:…
The study was performed to understand whether the immunity gained after vaccination or a prior infection was less effective or…
Advancing research on human immune systems in India to develop better vaccines
Dr Rama Akondy, Associate Professor of Biology, Ashoka University highlights that by fostering clinical and research partnerships,…
Haplo-cord treatment may offer lasting cure for over 37.7 mn HIV patients: GlobalData
However, more research will be required to assess if this is a cure as opposed to longer-term remission
Université de Paris and Institut Pasteur Association announce research partnership
The fields of biology and emerging infectious diseases, resistance to microbial agents and vaccinology are the first objectives…
US commences research on allergic reaction risk in Moderna, Pfizer vaccines
Several allergic reaction incidents, including serious episodes, known as anaphylaxis, have been reported in the US after…
COVID-19 vaccine from AstraZeneca/Oxford may see more global uptake due to good efficacy: GlobalData
GlobalData expects that the low cost of the AstraZeneca/Oxford vaccine will allow it to be used in low-income countries – where…